Lyra Therapeutics - Lyra Therapeutics
4.7 (131) · € 22.50 · En Stock
We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Lyra Therapeutics Stock: Promising Data For Sinus Treatment (NASDAQ:LYRA)
Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)
SEC Filing - Lyra Therapeutics, Inc.
Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lyra Therapeutics (@LyraTx) / X
Lyra Therapeutics Adds Vineeta Belanger, Ph.D., as Senior Vice President of Clinical Affairs
Lyra Therapeutics enrolls first patient in rhinosinusitis trial
Lyra Therapeutics - Lyra Therapeutics
Lyra Therapeutics (@LyraTx) / X
Lyra Therapeutics on X: We're developing LYR-210 for #ChronicRhinosinusitis (CRS), which causes sinus inflammation and debilitating symptoms for 3 months or more. Follow us to see how #LyraChallengesCRS. #CRSrelief6months https
Lyra Therapeutics Extends Gains After Insider Transactions Disclosures
SEC Filing - Lyra Therapeutics, Inc.
Lyra Therapeutics
